News & Media

5 September 2017

Ceva Swine Offer >

Complementarities between swine autogenous vaccines produced by Ceva Biovac and Ceva swine offer.

23 July 2017

Ceva continues to deliver double-digit growth >

Sales up 20% versus S1 2016, driven by organic growth and acquisitions

11 July 2017

Ceva Phylaxia inaugurates state of the art vaccine plant to support “Innovation with Impact” growth plan >

7,8 billion forint (€ 25m) investment will significantly increase production at its Budapest Campus

15 May 2017

Ceva announces important advances in the control of respiratory disease in poultry >

Ceva Vaccination Summit details new claims for IB Vaccines.

27 March 2017

Ceva shines light on the future with focus on innovation during VIV Asia 2017 >

Ceva’s teams brought innovation to the fore during VIV Asia 2017

12 March 2017

World Veterinary Association and Ceva Santé Animale announce the creation of the Global Animal Welfare Awards 2017 >

As global understanding and concern for animal welfare continues to change, so must the veterinary community evolve to embrace these changes and reflect societal expectations.

6 March 2017

Ceva honours rare livestock breeds during the French National Prize for Animal Agro biodiversity Awards ceremony >

The Fondation du Patrimoine and Ceva Santé Animale awarded the “Fondation du Patrimoine National Animal Agro-Biodiversity Prize” to 3 associations committed to preserving regional livestock breed, during the Paris International Agricultural Show.

20 February 2017

Ceva reinforces its position in China and swine through new joint-venture with EBVAC >

In the presence of the Chinese Prime Minister, Li Keqiang and French Prime Minister, Bernard Cazeneuve, Ceva Santé Animale (Ceva) and EBVAC today signed a joint-venture agreement to create a new business, Ceva EBVAC, focused on the swine sector.

8 February 2017

Ceva Santé Animale confirms its circle of virtuous growth in 2016 >

2016 was a year of sustained organic growth and major acquisitions. Consolidated sales reached €912m as the Ceva Group continued to achieve double-digit growth, cementing its position as the 6th. largest animal health company.

30 January 2017

Ceva stresses the need for continued innovation to ensure effective disease control at IPPE 2017 >

Vectormune® ND, vaccine for Newcastle Disease (ND) Cevac IBird®, for Infectious Bronchitis (IB) prevention will continue to lead offerings for effective and easily administered disease control.

Back to top